Brain scan illustration showing interconnected pathways for Parkinson's diagnosis.

Unlocking Parkinson's: How Brain Scans Could Revolutionize Early Diagnosis

Rhea Morgan in Health & Wellness December 2025 • 5 min read.

"New research highlights the potential of VBM technology in detecting subtle brain changes linked to cognitive decline in Parkinson's disease, offering a beacon of hope for early intervention."

Parkinson's disease (PD) is a neurodegenerative disorder affecting millions worldwide, primarily impacting motor skills. While motor symptoms like tremors and rigidity are well-known, cognitive impairment is increasingly recognized as a significant non-motor feature, often appearing early in the disease process. This cognitive decline can significantly impact a person's quality of life, making early detection and intervention crucial.

Traditional diagnostic methods for Parkinson's often rely on the manifestation of prominent motor symptoms, which can delay diagnosis until the disease has progressed. This is where advancements in neuroimaging techniques, such as voxel-based morphometry (VBM), offer a promising avenue for earlier and more accurate detection. VBM is a neuroimaging technique that detects changes in brain anatomy. By analyzing grey matter volume and white matter density, VBM can reveal subtle structural differences that may be indicative of early-stage Parkinson's disease, even before noticeable motor symptoms arise.

Recent research published in Neuroscience Letters delves into the potential of VBM technology in identifying changes in brain structure associated with cognitive impairment in Parkinson's disease. The study focuses on individuals with mild cognitive impairment (PD-MCI) and those with normal cognition (PD-CN), aiming to uncover specific brain patterns that differentiate these groups and highlight potential biomarkers for early diagnosis.

Decoding Brain Structure: How VBM Identifies Parkinson's-Related Changes

Brain scan illustration showing interconnected pathways for Parkinson's diagnosis.

The study, led by researchers at Guangdong General Hospital, involved analyzing brain MRI scans of 23 PD-MCI patients, 23 PD-CN patients, and 21 healthy controls. The researchers utilized VBM to compare grey matter volume and white matter density across these groups, seeking to identify specific brain regions exhibiting significant differences. The goal was to determine if VBM could effectively distinguish between individuals with and without cognitive impairment in Parkinson's disease.

The results revealed significant differences in brain structure among the groups. Compared to healthy controls, the PD-CN group showed grey matter atrophy primarily in the prefrontal lobe, limbic lobe, and left temporal gyrus. The PD-MCI group exhibited more extensive atrophy in the frontal lobe, limbic lobe, basal ganglia, and cerebellum. Furthermore, when compared to the PD-CN group, the PD-MCI group showed atrophy in the left-side middle temporal gyrus, inferior temporal gyrus, and frontal lobe.

Grey Matter Atrophy: Key regions affected included the frontal lobe, limbic system, medial temporal lobe, and basal ganglia.
White Matter Density Reduction: Primarily observed in the frontal lobe and caudate nucleus in PD-MCI patients compared to PD-CN patients.
Correlation with Cognitive Scores: Grey matter volume in the cingulate gyrus and limbic lobe correlated with MMSE scores (memory-related), while the frontal lobe, basal ganglia, and other regions correlated with MoCA scores (non-memory related).

These findings suggest that VBM technology can effectively detect subtle brain structural changes associated with cognitive impairment in Parkinson's disease. The identified regions, particularly the frontal and limbic lobes, play a crucial role in cognitive functions, and their atrophy may contribute to the cognitive decline observed in PD-MCI patients. Moreover, the study found correlations between specific brain regions and cognitive scores, further supporting the link between brain structure and cognitive performance.

A New Era of Early Detection and Personalized Treatment

This research provides compelling evidence for the potential of VBM technology as a valuable tool for early diagnosis and personalized treatment strategies in Parkinson's disease. By identifying specific brain regions affected by cognitive decline, clinicians can potentially tailor interventions to target these areas and slow down disease progression. This may involve cognitive therapies, medications, or lifestyle modifications designed to enhance cognitive function and improve the overall quality of life for individuals with Parkinson's disease.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1016/j.neulet.2017.08.028, Alternate LINK

Title: Changes Of Brain Structure In Parkinson’S Disease Patients With Mild Cognitive Impairment Analyzed Via Vbm Technology

Subject: General Neuroscience

Journal: Neuroscience Letters

Publisher: Elsevier BV

Authors: Yuyuan Gao, Kun Nie, Biao Huang, Mingjin Mei, Manli Guo, Sifen Xie, Zhiheng Huang, Limin Wang, Jiehao Zhao, Yuhu Zhang, Lijuan Wang

Published: 2017-09-01

Everything You Need To Know

What is VBM technology, and how does it help in the early detection of Parkinson's disease?

VBM, or voxel-based morphometry, is a neuroimaging technique. It examines brain anatomy by analyzing grey matter volume and white matter density. In the context of Parkinson's disease, VBM helps in early detection by identifying subtle structural changes in the brain associated with cognitive decline, even before noticeable motor symptoms appear. This allows for earlier intervention and treatment.

How does cognitive impairment relate to Parkinson's disease, and why is early detection of cognitive decline so important?

Cognitive impairment is increasingly recognized as a significant non-motor feature of Parkinson's disease, often emerging early in the disease process. This decline can significantly impact a person's quality of life. Early detection is crucial because it enables timely interventions, such as cognitive therapies, medications, or lifestyle modifications, potentially slowing disease progression and improving cognitive function.

What specific brain regions did the study find to be affected in Parkinson's patients, and how does this relate to cognitive function?

The study highlighted specific regions showing changes using VBM. Grey matter atrophy was observed in the frontal lobe, limbic system, medial temporal lobe, and basal ganglia. White matter density reduction was found in the frontal lobe and caudate nucleus in PD-MCI patients compared to PD-CN patients. These regions are crucial for cognitive functions. For example, the frontal and limbic lobes play important roles in cognitive processes, and their atrophy may contribute to cognitive decline in individuals with Parkinson's disease.

How did the researchers use VBM to differentiate between individuals with and without cognitive impairment in Parkinson's disease?

The researchers analyzed brain MRI scans using VBM to compare grey matter volume and white matter density across groups: PD-MCI patients, PD-CN patients, and healthy controls. They sought to identify specific brain regions exhibiting significant differences. The PD-MCI group showed more extensive atrophy in the frontal lobe, limbic lobe, basal ganglia, and cerebellum compared to PD-CN patients. Furthermore, the PD-MCI group showed atrophy in the left-side middle temporal gyrus, inferior temporal gyrus, and frontal lobe when compared to the PD-CN group. These differences helped in differentiating between the groups.

Based on the research, what are the potential implications of using VBM for personalized treatment strategies in Parkinson's disease?

The research suggests VBM can be a valuable tool for personalized treatment strategies. By identifying specific brain regions affected by cognitive decline, clinicians can potentially tailor interventions to target these areas. This may involve treatments such as cognitive therapies, medications, or lifestyle modifications designed to enhance cognitive function. This approach aims to slow disease progression and improve the overall quality of life for individuals with Parkinson's disease by focusing on the specific brain changes identified through VBM.